IRCT20111224008507N5
Recruiting
Phase 3
Double-blind placebo-controlled clinical trial of evaluating the effectiveness of Ivermectin in treatment of patients admitted with COVID-19 in 2021
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- COVID-19 infection.
- Sponsor
- Mazandaran University of Medical Sciences
- Enrollment
- 1000
- Status
- Recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with positive coronavirus rapid test or RT\-PCR
- •Age\>5 years
- •Weight \>15 kg
- •No treatment with antiviral drugs before and during the study
- •Informed consent for participation
Exclusion Criteria
- •Underlying liver and kidney disease
- •Patients with acquired immunodeficiency
- •Pregnancy and lactation
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
Evaluation of the effect of Ivermectin in treatment of outpatients with COVID-19IRCT20111224008507N4Mazandaran University of Medical Sciences1,000
Recruiting
Phase 2
Double-blind placebo-controlled clinical trial of thalidomide for chronic granulomatous disease-associated colitisJPRN-jRCT2031200236Kawai Toshinao8
Recruiting
Not Applicable
Double-blind placebo-controlled clinical trial of thalidomide for chronic granulomatous disease-associated colitisChronic granulomatous disease associated colitisJPRN-UMIN000029324ational Center for Child Heath and Development8
Completed
Phase 2
Frankincense effect on urinary disorders in multiple sclerosisMultiple sclerosis.Demyelinating diseases of the central nervous systemIRCT2015071023144N1Ahvaz Jundishapur University of Medical Sciences68
Completed
Phase 2
Effect of frankincense in treatment of eczemaIRCT20111105008013N5Ahvaz Jundishapur University of Medical Sciences, medicinal plants research center66